Details for Patent: 10,071,985
Which drugs does patent 10,071,985 protect, and when does it expire?
Patent 10,071,985 protects SUNLENCA, YEZTUGO, BIXLENVO, and BIXLENVO SUNLENCA STARTER PACK (COPACKAGED), and is included in six NDAs.
This patent has ninety-six patent family members in forty-four countries.
Summary for Patent: 10,071,985
| Title: | Therapeutic compounds |
| Abstract: | The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus. |
| Inventor(s): | Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. SAITO, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US15/680,041 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
Drugs Protected by US Patent 10,071,985
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | 10,071,985 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Gilead Sciences Inc | YEZTUGO | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 220018-001 | Jun 18, 2025 | RX | Yes | Yes | 10,071,985 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Gilead Sciences Inc | BIXLENVO | bictegravir sodium; lenacapavir sodium | TABLET;ORAL | 221104-001 | Aug 27, 2026 | RX | Yes | Yes | 10,071,985 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,071,985
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3347352 | ⤷ Start Trial | CA 2022 00052 | Denmark | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | 301212 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | PA2023501 | Lithuania | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
